Clinical Trials Logo

Clinical Trial Summary

The purpose of this investigation is to perform a pilot study assessing the safety and utility of intravenous ketamine as an adjuvant therapy in the emergency department setting for pediatric patients in acute status asthmaticus who have failed standard emergency therapy.


Clinical Trial Description

This is a pilot study of a cohort of 20 subjects to assess the feasibility, safety and efficacy of ketamine in status asthmaticus. The study will take place at the Augusta University's pediatric emergency department 24 hours a day. The attending physician who is clinically treating the patient will identify the patient as a potential study candidate (see inclusion criteria). Study team members will then be notified and obtain informed consent for potential participants who meet the inclusion/exclusion criteria. Once a patient in the Augusta University Children's Hospital of Georgia Pediatric Emergency Department is deemed a potential study subject, informed consent will be obtained by the research study team members. The patient and their parents will be provided with all the required information about the study including potential risks and benefits associated with participation. The information will be presented in a private setting in a language the patient understands. The patient and/or their parent/guardian will have opportunities to ask questions and will be given enough time to consider participation before providing consent. A document will be given to obtain assent/consent that reiterates all the information about the study (including reason for the study, risks, benefits, etc.) Study team members that will be actively involved in the study will be either pediatric emergency medicine faculty or pediatric emergency medicine fellows that are on staff. Patients that meet the inclusion and exclusion criteria will have ketamine 1 mg/kg IV bolus administered once informed consent has been obtained. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03338205
Study type Interventional
Source Augusta University
Contact
Status Withdrawn
Phase Phase 3
Start date January 2020
Completion date January 2022

See also
  Status Clinical Trial Phase
Completed NCT02872597 - Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus Phase 1
Terminated NCT02966184 - Comparison of Albuterol for Status Asthmaticus Phase 4
Enrolling by invitation NCT00750568 - Intravenous Terbutaline in Severe Status Asthmaticus N/A
Completed NCT00124995 - Trial of Terbutaline for the Treatment of Status Asthmaticus in Children Phase 4
Recruiting NCT05819541 - Treating Exacerbations of Asthma With Oral Montelukast in Children Phase 2
Completed NCT01524198 - The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room Phase 2/Phase 3
Terminated NCT02780479 - Steroids in Children Hospitalized With Asthma Phase 4
Withdrawn NCT01403428 - Non Invasive Positive Pressure Ventilation in Status Asthmaticus Phase 2
Terminated NCT00683449 - Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma Phase 2
Withdrawn NCT03219736 - NiPPV in the Treatment of Acute Asthma Exacerbations N/A
Completed NCT00722020 - HFCWO in Hospitalized Asthmatic Children N/A
Completed NCT02302261 - Pleth Variability and Asthma Severity in Children N/A
Recruiting NCT01770899 - Evaluation Montelukast in the Treatment of Status Asthmaticus N/A
Withdrawn NCT01188473 - Early Noninvasive Positive Pressure Ventilation in Children With Status Asthmaticus Phase 1
Withdrawn NCT04656587 - BPAP in Pediatric Asthma Pilot Study N/A
Completed NCT04929626 - Different Doses of Nebulized Magnesium Sulphate in Status Asthmaticus Phase 1
Completed NCT00623688 - Effectiveness and Cost Study Comparing Two Ways to Deliver Albuterol for the Treatment of Asthma in the Hospital N/A
Recruiting NCT00491790 - Montelukast With Status Asthmaticus, Ages 2-5 Phase 2/Phase 3
Recruiting NCT00494572 - Montelukast With Status Asthmaticus, Ages 6-18 Phase 2/Phase 3
Completed NCT00279786 - B2-Adrenergic Receptor Polymorphisms